Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Join the Blood Cancer Biology and Immunotherapy group at the University of Basel, a joint venture with University Hospitals Basel. We seek a highly motivated postdoctoral researcher (100%) to study how cellular metabolism shapes leukemia persistence, immune evasion, and anti-leukemia immunity within ERC LIFE project LIFE - Targeting bioactive lipids to overcome leukemia immune evasion and improve stem cell transplantation outcomes.
Start date is 1 February 2027 or upon agreement.
Organisation/Company University of Basel Research Field Biological sciences » Other Chemistry » Biochemistry Medical sciences » Other Researcher Profile Recognised Researcher (R2) Application Deadline 27 Nov 2026 - 22:59 (UTC) Country Switzerland Type of Contract Temporary Job Status Full-time Is the job funded through the EU Research Framework Programme? Horizon Europe - ERC Is the Job related to staff position within a Research Infrastructure? No
As a joint venture of the University of Basel and the University Hospitals Basel, the Department of Biomedicine (DBM) brings together basic and clinical scientists to advance the understanding of health and disease.
We are home to more than 67 research groups and over 800 employees across six locations in the heart of Basel. Our collaborative and international environment foster innovation, excellence, and impactful research.
The Blood Cancer Biology and Immunotherapy group, led by Prof. Petya Apostolova ( www.apostolovalab.com ), is seeking a highly motivated postdoctoral researcher (100%) to investigate how cellular metabolism shapes leukemia persistence, immune evasion, and anti-leukemia immunity. This position is funded within our recent European Research Council (ERC) Starting Grant project LIFE - Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes.
Start date: 1. February 2027 or upon agreement
Duration: 1 year, with possibility of extension and long-term perspective
Join our community and help shape the future of biomedicine.
Research environment
The Apostolova Lab is based at the Department of Biomedicine, University of Basel, in a highly interactive environment spanning cancer biology, immunology, genomics, metabolism, and translational medicine. Our group combines mechanistic leukemia models with metabolism, immunology, and multi-omics to understand how leukemia cells adapt to therapeutic pressure and interact with the immune system.
The successful candidate will have access to state-of-the-art infrastructure for flow cytometry, animal experimentation, advanced microscopy, single-cell and spatial technologies, mass spectrometry-based metabolomics and lipidomics, and computational biology, together with extensive opportunities for local and international collaboration. Mentorship and respect for human values, including diversity, equity, and inclusiveness, are driving forces of our group.
Your responsibilities will include:
Experimental approaches in our group include in vivo leukemia and allogeneic hematopoietic stem cell transplantation models, liquid chromatography-mass spectrometry metabolomics and lipidomics, functional genomics and CRISPR screens, spectral flow cytometry, cell sorting, bulk, single-cell and spatial transcriptomics, and functional immune and metabolic assays. We are looking for an experimental scientist with strong intellectual curiosity, knowledge and practical expertise in tumor immnology, and an interest in mechanistic cancer research. Applicants should have:
Experience in leukemia research, tumor immunology, metabolism, CRISPR screening, or histology is an advantage but not required. We are particularly interested in candidates who want to take intellectual ownership of an ambitious project, pursue mechanistic questions, and develop their own scientific profile at the interface of tumor immunology and metabolism.
Applications from candidates with strong backgrounds in experimental hematology, tumor immunology, or cancer metabolism are particularly encouraged.